Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi
暂无分享,去创建一个
[1] M. Vaara. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria , 1993, Antimicrobial Agents and Chemotherapy.
[2] A. Barbour,et al. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies , 1992, Journal of clinical microbiology.
[3] A. G. Barbour,et al. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization , 1992, The Journal of experimental medicine.
[4] Jerome J. Schentag,et al. Tissue-directed pharmacokinetics. , 1991, The American journal of medicine.
[5] S. Malawista,et al. Lyme disease: recommendations for diagnosis and treatment. , 1991, Annals of internal medicine.
[6] R. C. Johnson,et al. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. , 1989, Reviews of infectious diseases.
[7] J. Halperin,et al. A perspective on the treatment of Lyme borreliosis. , 1989, Reviews of infectious diseases.
[8] K.,et al. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy , 1989, Antimicrobial Agents and Chemotherapy.
[9] A. Barbour. Isolation and cultivation of Lyme disease spirochetes. , 1984, The Yale journal of biology and medicine.
[10] A. Steere,et al. Treatment of the early manifestations of Lyme disease. , 1983, Annals of internal medicine.
[11] P. Thompson,et al. In vitro inhibition of Borrelia burgdorferi growth by antibodies. , 1993, The Journal of infectious diseases.
[12] H. Neu. The development of macrolides: clarithromycin in perspective. , 1991, The Journal of antimicrobial chemotherapy.
[13] G. Foulds,et al. The pharmacokinetics of azithromycin in human serum and tissues. , 1990, The Journal of antimicrobial chemotherapy.